This state-of-art technology will help pulmonologists to diagnose lung cancer in the very early stages helping the patient get an early surgical resection
Prashant comes with over 17 years of experience in the health, health insurance and other allied healthcare sectors
Dr. Raman has succeeded Victoria Richon
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
The surgery was helmed by Prof. Dr. Vishwanath Pai, Sr. Consultant, Department of Minimally Invasive Surgery, Prashanth Hospitals, Velachery
The cash consideration for the acquisition is US$ 18 million.
Doctors can now analyse their historical prescriptions within a few clicks enabling them to identify different cohorts of patients and the treatment given to them
Subscribe To Our Newsletter & Stay Updated
